A Pure Estrogen Antagonist Inhibits Cyclin E-Cdk2 Activity in MCF-7 Breast Cancer Cells and Induces Accumulation of p130-E2F4 Complexes Characteristic of Quiescence
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Estrogen antagonists inhibit cell cycle progression in estrogen-responsive cells, but the molecular mechanisms are not fully defined. Antiestrogen-mediated G(0)/G(1) arrest is associated with decreased cyclin D1 gene expression, inactivation of cyclin D1-cyclin dependent kinase (Cdk) 4 complexes, and decreased phosphorylation of the retinoblastoma protein (pRb). We now show that treatment of MCF-7 breast cancer cells with the pure estrogen antagonist ICI 182780 results in inhibition of cyclin E-Cdk2 activity prior to a decrease in the G(1) to S phase transition. This decrease was dependent on p21(WAF1/Cip1) since treatment with antisense oligonucleotides to p21 attenuated the effect. Recruitment of p21 to cyclin E-Cdk2 complexes was in turn dependent on decreased cyclin D1 expression since it was apparent following treatment with antisense cyclin D1 oligonucleotides. To define where within the G(0) to S phase continuum antiestrogen-treated cells arrested, we assessed the relative abundance and phosphorylation state of pocket protein-E2F complexes. While both pRb and p107 levels were significantly decreased, p130 was increased 4-fold and was accompanied by the formation of p130.E2F4 complexes and the accumulation of hyperphophorylated E2F4, putative markers of cellular quiescence. Thus, ICI 182780 inhibits both cyclin D1-Cdk4 and cyclin E-Cdk2 activity, resulting in the arrest of MCF-7 cells in a state with characteristics of quiescence (G(0)), as opposed to G(1) arrest.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The nuclear receptor superfamily: the second decade
Mangelsdorf, D. J., Thummel, C., Beato, M., Herrlich, P., Schütz, G., Umesono, K., Blumberg, B., Kastner, P., Mark, M., Chambon, P., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90199-x · Cited by 6,964
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115
The regulation of E2F by pRB-family proteins.
Dyson, N. (1998) · Genes & Development · doi:10.1101/gad.12.15.2245 · Cited by 2,317
Harbour, J. W., Luo, R. X., Santi, A. D., Postigo, A. A., & Dean, D. C. (1999) · Cell · doi:10.1016/s0092-8674(00)81519-6 · Cited by 1,057
Sherr, C. J. (1995) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(00)89005-2 · Cited by 980
Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta.
Reynisdóttir, I., Polyak, K., Iavarone, A., & Massagué, J. (1995) · Genes & Development · doi:10.1101/gad.9.15.1831 · Cited by 962
Smith, E. J., Leone, G., DeGregori, J., Jakoi, L., & Nevins, J. R. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.12.6965 · Cited by 218
Cited by
Carroll, J. S., Liu, X. S., Brodsky, A. S., Li, W., Meyer, C. A., Szary, A. J., Eeckhoute, J., Shao, W., Hestermann, E. V., Geistlinger, T. R., et al. (2005) · Cell · doi:10.1016/j.cell.2005.05.008 · Cited by 1,384
Self-citationBiological determinants of endocrine resistance in breast cancer
Musgrove, E. A., & Sutherland, R. L. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2713 · Cited by 1,252
Self-citationFOXA1 is a key determinant of estrogen receptor function and endocrine response
Hurtado, A., Holmes, K. A., Ross-Innes, C. S., Schmidt, D., & Carroll, J. S. (2011) · Nature Genetics · doi:10.1038/ng.730 · Cited by 953
Self-citationThe Role of Prolactin in Mammary Carcinoma
Clevenger, C. V., Furth, P. A., Hankinson, S. E., & Schuler, L. A. (2003) · Endocrine Reviews · doi:10.1210/er.2001-0036 · Cited by 545
Opposing Action of Estrogen Receptors α and β on Cyclin D1 Gene Expression
Liu, M.-M., Albanese, C., Anderson, C. M., Hilty, K., Webb, P., Uht, R. M., Price, R. H., Pestell, R. G., & Kushner, P. J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m201829200 · Cited by 422
Yu, K., Toral-Barza, L., Discafani, C., Zhang, W. G., Skotnicki, J., Frost, P., & Gibbons, J. J. (2001) · Endocrine-related cancer · doi:10.1677/erc.0.0080249 · Cited by 420
Jordan, V. C. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm020450x · Cited by 396
Selective Estrogen Receptor Modulators
Frasor, J., Stossi, F., Danes, J. M., Komm, B., Lyttle, C. R., & Katzenellenbogen, B. S. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3326 · Cited by 395
Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers
Finn, R. S., Aleshin, A., & Slamon, D. J. (2016) · Breast Cancer Research · doi:10.1186/s13058-015-0661-5 · Cited by 368
Estrogen and antiestrogen regulation of cell cycle progression in breast cancer cells
Doisneau-Sixou, S. F., Sergio, C. M., Carroll, J. S., Hui, R., Musgrove, E. A., & Sutherland, R. L. (2003) · Endocrine Related Cancer · doi:10.1677/erc.0.0100179 · Cited by 333
Self-citationRegulation of ERBB2 by oestrogen receptor–PAX2 determines response to tamoxifen
Hurtado, A., Holmes, K. A., Geistlinger, T. R., Hutcheson, I. R., Nicholson, R. I., Brown, M., Jiang, J., Howat, W. J., Ali, S., & Carroll, J. S. (2008) · Nature · doi:10.1038/nature07483 · Cited by 321
Self-citationThangavel, C., Dean, J. L., Ertel, A., Knudsen, K. E., Aldaz, C. M., Witkiewicz, A. K., Clarke, R., & Knudsen, E. S. (2011) · Endocrine Related Cancer · doi:10.1530/erc-10-0262 · Cited by 302
“Specifically, the withdrawal of estrogen (mimicking aromatase inhibitors) or use of estrogen antagonists (e.g. ICI 182 780 or Tamoxifen) results in an arrest in the G0/G1 phase of the cell cycle (Watts et al. 1995, Carroll et al. 2000, Foster et al. 2001, Markey et al. 2007).”
Qin, Q., Fan, J., Zheng, R., Wan, C., Mei, S., Wu, Q., Sun, H., Brown, M., Zhang, J., Meyer, C. A., et al. (2020) · Genome Biology · doi:10.1186/s13059-020-1934-6 · Cited by 296
Pathways to tamoxifen resistance
Riggins, R. B., Schrecengost, R. S., Guerrero, M. S., & Bouton, A. H. (2007) · Cancer Letters · doi:10.1016/j.canlet.2007.03.016 · Cited by 277
Sutherland, R. L., & Musgrove, E. A. (2004) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1023/b:jomg.0000023591.45568.77 · Cited by 258
Self-citationThe androgen receptor is a tumor suppressor in estrogen receptor–positive breast cancer
Hickey, T. E., Selth, L. A., Chia, K. M., Laven-Law, G., Milioli, H. H., Roden, D., Jindal, S., Hui, M., Finlay-Schultz, J., Ebrahimie, E., et al. (2021) · Nature Medicine · doi:10.1038/s41591-020-01168-7 · Cited by 257
Self-citationNew Histone Incorporation Marks Sites of UV Repair in Human Cells
Polo, S. E., Roche, D., & Almouzni, G. (2006) · Cell · doi:10.1016/j.cell.2006.08.049 · Cited by 253
Estrogens and cell-cycle regulation in breast cancer
Foster, J. S., Henley, D. C., Ahamed, S., & Wimalasena, J. (2001) · Trends in Endocrinology & Metabolism · doi:10.1016/s1043-2760(01)00436-2 · Cited by 203
Asf1b, the necessary Asf1 isoform for proliferation, is predictive of outcome in breast cancer
Corpet, A., De Koning, L., Toedling, J., Savignoni, A., Berger, F., Lemaître, C., O'Sullivan, R. J., Karlseder, J., Barillot, E., Asselain, B., et al. (2011) · The EMBO Journal · doi:10.1038/emboj.2010.335 · Cited by 187
“With an anti-estrogen treatment, MCF7 breast carcinoma cells enter in quiescence (Carroll et al, 2000).”
BackgroundCyr61, a Member of CCN Family, Is a Tumor Suppressor in Non-Small Cell Lung Cancer
Tong, X., Xie, D., O'Kelly, J., Miller, C. W., Muller-Tidow, C., & Koeffler, H. P. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m107878200 · Cited by 132
Lycopene inhibition of IGF-induced cancer cell growth depends on the level of cyclin D1
Nahum, A., Zeller, L., Danilenko, M., Prall, O. W. J., Watts, C. K. W., Sutherland, R. L., Levy, J., & Sharoni, Y. (2006) · European Journal of Nutrition · doi:10.1007/s00394-006-0595-x · Cited by 99
“Interestingly, many anticancer agents, including those used for breast cancer therapy, convey their inhibitory effect in G1 phase primarily by reducing cyclin D1 levels (for example, pure antiestrogens [12, 13 ], tamoxifen [14], retinoids [15, 16], as well as progestins [17], and 1,25-dihydroxyvitamin D3 [18]).”
BackgroundSelf-citationTong, X., O'Kelly, J., Xie, D., Mori, A., Lemp, N., McKenna, R., Miller, C. W., & Koeffler, H. P. (2004) · Oncogene · doi:10.1038/sj.onc.1207628 · Cited by 86
“These CDKs phosphorylate pocket Oncogene proteins and inhibition of CDKs leads to a G0–G1 arrest of the cell cycle (Harper et al., 1993; Xiong et al., 1993; Morgan, 1995; Weinberg, 1995). p130 protein accumulates as a result of the loss of CDK activity (Carroll et al., 2000).”
BackgroundRetracted
Metadata
- Authors
- Carroll, J. S., Prall, O. W. J., Musgrove, E. A., & Sutherland, R. L.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2000-12
- Volume
- 275
- Issue
- 49
- Pages
- 38221-38229
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2073689111
- Cited by
- 143
- References
- 7
- FWCI
- 5.54
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.